Beyond managing symptoms: 5 European companies redefining what's possible in chronic disease

Europe is entering a new era in the fight against chronic disease. As populations age and life expectancy continues to rise, conditions such as cardiovascular disease, diabetes, respiratory illness, and inflammatory disorders are placing increasing pressure on healthcare systems across the continent. At the same time, the scale of investment reflects the urgency of the challenge. The European chronic disease management market was valued at more than USD 400 billion in 2025 and is projected to grow at a compound annual rate of 13.7% through 2033, driven by increasing demand for more effective, technology-enabled models of care.

Alongside this growth, the science is changing. Advances in precision medicine, biologics, AI-assisted drug discovery, and next-generation therapeutics are reshaping how many chronic conditions are understood and treated. Rather than focusing solely on managing symptoms, researchers are increasingly targeting the underlying mechanisms of disease, opening the door to treatments that have the potential to improve long-term outcomes in ways that would have seemed unlikely only a decade ago.

Across Europe, a number of life sciences companies are driving this progress through breakthroughs in cardiometabolic disease, respiratory medicine, immunology, and precision diagnostics. The five organisations below are helping to shape the next chapter of chronic disease care, each contributing in different ways to how these conditions are understood, treated, and managed.

Novo Nordisk (Denmark)

Few companies have shaped the future of chronic disease treatment as profoundly as Novo Nordisk. Its GLP-1 therapies, Ozempic and Wegovy, have transformed the management of diabetes and obesity while demonstrating benefits that extend into cardiovascular disease and other related conditions. The landmark SELECT trial showed semaglutide reduced the risk of major cardiovascular events in overweight and obese adults without diabetes, highlighting the potential of GLP-1 therapies to target the underlying biology shared across multiple chronic diseases.

As demand continues to grow, Novo Nordisk is expanding its manufacturing capacity and advancing next-generation therapies, reinforcing its position at the forefront of cardiometabolic innovation and the shift from symptom management towards disease modification. Its work reflects a broader shift towards therapies that address the shared biology underlying multiple chronic diseases.

Boehringer Ingelheim (Germany)

Boehringer Ingelheim has built one of Europe's strongest chronic disease pipelines by focusing on areas where patients have historically had few treatment options. In respiratory medicine, its investigational therapy nerandomilast became the first treatment in more than a decade to meet its Phase III primary endpoint in idiopathic pulmonary fibrosis (IPF), offering renewed hope for patients living with the progressive lung disease.

The company's impact extends beyond respiratory care. Its SGLT2 inhibitor Jardiance, co-developed with Eli Lilly, has evolved from a diabetes treatment into an important therapy for heart failure and chronic kidney disease, reflecting the growing focus on medicines that address interconnected chronic conditions rather than a single disease in isolation. Together, these programmes demonstrate how innovation is reaching diseases that have historically seen few therapeutic breakthroughs.

Novartis (Switzerland)

Novartis is helping redefine cardiovascular care through precision medicine, focusing on therapies that target the underlying drivers of disease rather than simply managing risk factors. Leqvio (inclisiran), a small interfering RNA (siRNA) therapy administered twice yearly for lowering LDL cholesterol, offers a new approach to long-term cardiovascular risk management by improving treatment adherence alongside clinical effectiveness.

The company is also advancing pelacarsen, an investigational therapy targeting lipoprotein(a) (Lp(a)), a genetically inherited risk factor that affects around one in five people worldwide and has long lacked an approved treatment. Together, these programmes reflect a growing shift towards more personalised approaches to preventing and managing chronic cardiovascular disease.Together, these programmes reflect a growing shift towards more personalised approaches to preventing and managing chronic cardiovascular disease.

Sanofi (France)

Sanofi has demonstrated how a single breakthrough therapy can reshape the treatment of multiple chronic diseases. Its biologic medicine Dupixent (dupilumab), developed with Regeneron, was first approved for atopic dermatitis but has since expanded into severe asthma, chronic rhinosinusitis, eosinophilic oesophagitis, and more recently COPD with type 2 inflammation. By targeting the underlying inflammatory pathways shared across these conditions, Dupixent has helped shift the focus from managing symptoms to addressing the root causes of disease.

As Sanofi continues to explore new indications, its approach reflects a broader trend in chronic disease research: understanding the common biological mechanisms that connect different conditions and using that knowledge to develop more precise, long-term treatments. Its success illustrates how understanding shared biological pathways is reshaping the treatment of chronic inflammatory diseases.

Roche (Switzerland)

Roche is helping advance chronic disease care by strengthening how cardiometabolic diseases are detected, monitored, and managed. Through its integrated diagnostics portfolio, the company supports earlier diagnosis, risk assessment, and disease monitoring across conditions including cardiovascular disease and diabetes, enabling clinicians to make more informed treatment decisions throughout the patient journey.

Alongside its diagnostics expertise, Roche continues to invest in targeted therapies for chronic inflammatory diseases, including lupus nephritis. By combining diagnostics with precision therapeutics, Roche is helping move chronic disease management towards more personalised care, where treatment decisions are increasingly tailored to the individual patient rather than the condition alone.

While these companies are taking different approaches to chronic disease, they share a common ambition: moving beyond treating symptoms to addressing the biological mechanisms that drive disease. Whether through precision medicine, targeted biologics, RNA therapies, or advanced diagnostics, the focus is increasingly on improving long-term outcomes rather than simply managing progression.

They also reflect a broader shift in how innovation happens. Advances in AI-assisted drug discovery are accelerating target identification, precision diagnostics are enabling more personalised treatment decisions, and large-scale manufacturing investments are helping to bring increasingly complex therapies to patients. Together, these developments are changing not only what treatments are available, but how chronic diseases are understood and managed across Europe.

Scientific breakthroughs alone are not enough to transform patient care. Bringing new therapies from the laboratory to the clinic depends on the people responsible for developing, manufacturing, regulating, and commercialising them.

Across Europe, demand continues to grow for professionals in regulatory affairs, clinical development, medical affairs, quality, manufacturing, and MSAT, particularly those with experience in biologics, cardiometabolic therapies, and advanced manufacturing. As more programmes move into late-stage development and commercial production, organisations are competing for increasingly specialised talent with the expertise to navigate complex regulatory requirements and scale innovation successfully.

In our experience supporting life sciences organisations across the Netherlands, Switzerland, Germany, and Denmark, access to specialist talent is becoming a key differentiator. The companies best positioned to deliver the next generation of chronic disease treatments are not only investing in science, but also in the teams that turn scientific progress into real-world patient impact.

The future of chronic disease treatment will be shaped by more than scientific discovery alone. Success will depend on translating promising research into therapies that improve outcomes for millions of people living with long-term conditions.

The companies highlighted here are demonstrating what that future could look like, combining advances in biology, technology, and precision medicine to tackle some of healthcare's biggest challenges. As innovation continues to accelerate, the organisations that bring together scientific excellence with the right expertise will be best placed to shape the next chapter of chronic disease care.